title: Tofacitinib, an Oral Janus Kinase Inhibitor: Perspectives in Dermatology.
abstract: BACKGROUND
  Tofacitinib (formerly known as CP-690,550, CP690550, tasocitinib), a novel selective immunosuppressant, is a small molecule classified as Janus kinase inhibitor. The aim of this review article is to present updated data summary on the tofacitinib in the field of dermatology.
  
  
  METHODS
  We undertook a structured search of bibliographic databases for peer-reviewed scientific articles, including review articles, original research articles as well as case report articles based on inclusion/exclusion criteria. Technical reports on tofacitinib from U.S. Food and Drug Administration and European Medical Agency were also included.
  
  
  RESULTS
  Forty-three papers were included in this review. We report current data on tofacitinib chemical properties, pharmacology, non-clinical toxicity, as well as efficacy and safety in potential new indications in dermatology: psoriasis, alopecia areata, vitiligo, atopic dermatitis and nail dystrophy associated with alopecia areata.
  
  
  CONCLUSIONS
  JAK/STAT pathway has an important role in the pathogenesis of psoriasis, alopecia areata, atopic dermatitis, and vitiligo. Despite encouraging efficacy, due to concerns about the overall safety profile of tofacitinib, additional studies will have to determine the adequate risk-to-benefit ratio.
authors.affiliation: Department of Dermatovenereology, University Hospital Center Zagreb, School of Medicine, University of Zagreb, Salata 4, 10000 Zagreb. Croatia.
authors.forename: Kresimir
authors.initials: K
authors.lastname: Kostovic
authors.affiliation: Department of Infectious Diseases and Dermatovenereology, General Hospital Sibenik, Stjepana Radica 83, 22000 Sibenik. Croatia.
authors.forename: Sandra J
authors.initials: SJ
authors.lastname: Gulin
authors.affiliation: Department of Dermatovenereology, University Hospital Center Zagreb, School of Medicine, University of Zagreb, Salata 4, 10000 Zagreb. Croatia.
authors.forename: Zrinka B
authors.initials: ZB
authors.lastname: Mokos
authors.affiliation: Department of Dermatovenereology, University Hospital Center Zagreb, School of Medicine, University of Zagreb, Salata 4, 10000 Zagreb. Croatia.
authors.forename: Romana
authors.initials: R
authors.lastname: Ceovic
mesh_terms: D000284:Administration, Oral; D000506:Alopecia Areata / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D003876:Dermatitis, Atopic / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D006801:Humans; D053612:Janus Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism*; D010880:Piperidines / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D011565:Psoriasis / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D011743:Pyrimidines / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D011758:Pyrroles / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D015398:Signal Transduction / Q000187:drug effects; D012871:Skin Diseases / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D014820:Vitiligo / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology
chemical_list: D010880:Piperidines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D011758:Pyrroles; C479163:tofacitinib; D053612:Janus Kinases
keywords: CP690550; JAK/STAT pathway; Tofacitinib; alopecia
  areata; protein kinase inhibitor; psoriasis; small molecule; vitiligo